中国全科医学2017，Vol.20Issue(34)：4278-4283,6.DOI:10.3969/j.issn.1007-9572.2017.34.013
二甲双胍联合艾塞那肽治疗新诊断超重2型糖尿病的疗效观察
Response to Metformin Combined with Exenatide in Newly Diagnosed Overweight Type 2 Diabetic Patients
摘要
Abstract
Objective To explore the effect and safety of 12 - week metformin combined with exenatide (ME) treatment for newly diagnosed overweight type 2 diabetic patients,and to investigate the subsequent response in these patients after stop using exenatide for 12 weeks following 12 - week ME treatment. Methods The enrolled participants were 50 cases of overweight newly diagnosed type 2 diabetic patients. Body weight,BMI,fasting plasma glucose (FPG),2 h postprandial plasma glucose (2 hPG),glycosylated hemoglobin (HbA 1c ),triacylglycerol (TG),total cholesterol (TC),low - density lipoprotein (LDL),insulin,C - peptide,2 h postprandial C - peptide (2 hCP),adiponectin,resistin,tumor necrosis factor- alpha (TNF - α),and other biochemical indices were measured,and HOMA - IR was calculated at baseline,at 12 weeks of ME treatment and at 12 weeks after stopping using exenatide following 12 - week ME treatment. Comparisons were made between the first and second measurement data,as well as between the second and third measurement data using paired t - test. Results The body weight,BMI,FPG,2 hPG,HbA 1c ,TG,TC,LDL,HOMA - IR,resistin,TNF - α decreased but adiponectin increased significantly at the end of 12 - week ME treatment (P < 0. 05). FPG,2 hPG,HbA 1c ,HOMA - IR and TNF - αincreased (P < 0. 05)but other indices did not change significantly at 12 weeks after stopping using exenatide following 12 -week ME treatment (P > 0. 05). Conclusion Early ME treatment may be a safe and effective regimen for newly diagnosed overweight type 2 diabetic patients.关键词
超重/糖尿病,2型/艾塞那肽/二甲双胍Key words
Overweight/Diabetes mellitus,type 2/Exenatide/Metformin分类
医药卫生引用本文复制引用
魏伟平,全会标,陈道雄,陈开宁..二甲双胍联合艾塞那肽治疗新诊断超重2型糖尿病的疗效观察[J].中国全科医学,2017,20(34):4278-4283,6.基金项目
海南省重点科技计划项目(ZDXM20120114) （ZDXM20120114）
